Printer Friendly

Fluoroquinolone resistance among Neisseria gonorrhoeae isolates from Shanghai, China: Detection of quinolone resistance-determining region mutations.

Background & objectives: Fluoroquinolone has a broad spectrum of antimicrobial activity, and is widely used for gonorrhoea treatment. However, its efficacy can be compromised by the drug-resistance property of Neisseria gonorrhoeae isolates. Most resistant cases of N. gonorrhoeae are associated with mutations in the quinolone-resistance-determining-region (QRDR) within genes o fgyrA and parC. This study was undertaken to describe resistance profile of N. gonorrhoeae to fluoroquinolones in Shanghai, P.R. of China, and also associated resistance mutations in gyrA and parC.

Methods: Eighty N. gonorrhoeae isolates were collected from Shanghai Skin Disease & Sexually Transmitted Disease Hospital or DongFang Hospital during April 2005 to April 2006 in Shanghai, P.R. of China. The minimum inhibitory concentrations (MIC) of fluoroquinolones for these isolates were determined by an agar dilution method. Mutation patterns within gyrA and parC were determined by direct sequencing or by using established restriction fragment length polymorphisms (RFLP) methods.

Results: Ninety five per cent (76 of 80) of isolates were resistant, 3.75 per cent (3 of 80) intermediate resistant, and 1.25 per cent (1 of 80) were sensitive to fluoroquinolone drug ciprofloxacin. Sequencing and RFLP analysis of gyrA and parC revealed that all resistant isolates had dual mutations of S91F and D95A/G/N in gyrA. Some isolates had an extra mutation within parC either of D86N, $87N or E91A/G. Mutation patterns for gyrA and parC were significantly (P<0.05) associated with MICs level.

Interpretation & conclusions: Mutations of S91F and D95A/G/N in gyrA combined with $87N in parC was the most prevalent mutation pattern of fluoroquinolone resistant N. gonorrhoeae isolates. This mutation pattern was associated with a high level of quinolone resistance (MIC >16.0 [micro]g/ml) which can serve as a maker for quinolone-resistance prediction in Shanghai, P.R. of China.

Key words Fluoroquinolone--gyrA--Neisseria gonorrhoeae--parC--resistance

**********

Gonorrhoea is a sexually transmitted disease due to infection by bacterium Neisseria gonorrhoeae. Patients are usually treated with antibiotics. In China, antibiotic-resistant N. gonorrhoeae isolates are common due to irregular prescription of antibiotics, and have become an important public health concern (1,2).

Fluoroquinolones are frequently used in treatment for gonorrhoea, with ciprofloxacin and ofloxacin being used as primary drugs in a number of countries. N. gonorrhoeae was highly susceptible to ciprofloxacin when this drug was first introduced in 1980s. In the last few years, a number of gonococci with decreased susceptibility or clinically significant resistance to fluoroquinolones including ciprofloxacin have been isolated all over the world (3-8).

The mechanism of fluoroquinolone-resistance of N. gonorrhoeae has been a subject of investigation (9,10). One possibility is that the gonococcus involves mutations in the quinolone-resistance-determining-region (QRDR) of gyrA and the analogous of parC locus on the chromosome. These mutations result in altered GyrA and ParC proteins (9,11,12). Altered proteins can no longer be bound by fluoroquinolones, therefore, the drug is unable to inhibit DNA replication and bacterium becomes less susceptible. The level of drug susceptibility appears to correlate with the location and number of mutations presented (12). This mechanism is analogous to those observed in Escherichia coli or other bacterial This study was carried out to provide further evidence of the correlation of the pattern of mutation of gyrA and parC genes with the drug resistant of N. gonorrhoeae in isolates from Shanghai, P.R.China, where higher resistance to ciprofloxacin has been reported than those from other regions of the world (6).

Material & Methods

Bacterial isolates: N. gonorrhoeae isolates were obtained from urethral and endocervical swabs, taken from gonorrhoea patients who had visited Shanghai Skin Disease & Sexually Transmitted Disease Hospital or DongFang Hospital during the period of April 2005 to April 2006. A total of 435 patients visited these hospitals for sexually transmitted disease treatment during the study period. Case exclusion criteria included: (i) co-infection with pathogens other than N. gonorrhoeae; and (ii) antibiotic treatment for the current episode of infection before enrollment. All eligible patients gave written consents for their enrollment. A total of 80 isolates were successfully obtained from patients who met the inclusion requirements of this study. Reference strains WHO-A, B, C, D and E were provided by National Institute for Control of Pharmaceuticals and Biological Products (Beijing, P.R. of China).

Antibiotics: Ofloxacin (Daiichi Sankyo Ltd, Tokyo, Japan), lomefloxacin (Abbott Ltd, Illinois, United States) and ciprofloxacin (Bayer Ltd, Leverkusen, Germany) were provided by National Institute for Control of Pharmaceuticals and Biological Products (Beijing, P.R. of China).

Minimum inhibitory concentration (MIC): An agar dilution method recommended by the WHO Western Pacific Regional Resistance Surveillance Programme was used to determine minimum inhibitory concentration (MIC) (13). MIC tests were performed on chocolate agar base (Oxiod Ltd, Basingstoke, United Kingdom) supplemented with 10 per cent defibrinated fresh sheep blood (Zhongqing Biotech Inc. Ltd, Shanghai, China) and 1 per cent Iso VitaleX (Oxiod Ltd, Basingstoke, United Kingdom). Agar plates were inoculated with [10.sup.8] cfu/ml bacteria, incubated at 36[degrees]C with 5 per cent C[O.sub.2] for 36 h. Antibiotics were diluted in agar at concentrations from 0.002 to 16.0 [micro]g/ml for ciprofloxacin, 0.0078 to 16.0 [micro]g/ml for ofloxacin and 0.0078 to 16.0 [micro]g/ml for lomefloxacin. Reference strains (WHO A-E) with known MICs were co-tested with samples as control. MICs were determined as the lowest antibiotic concentration that had completely inhibited bacteria growth (14).

Amplification of quinolone-resistance-determining-region: Oligo primers were synthesized by Sangon Biotech Co, Ltd. (Shanghai, P.R. of China). Primers for amplification of QRDR within gyrA were: Forward 5'-CGC GAT GCA CGA GCT GAA AAA-3', Reverse 5'-ATT TCG GTA TAG CGC ATG GCT G-3'; for QRDR within parC were: Forward 5'-GTT TCA GAC GGC CAA AAG CCC-3', Reverse 5'-GGA CAA CAG CAA TTC CGC AAT-3'. PCRs were carried on using 25 [micro]l volume that consisted of 12.5 [micro]l 2XPCR master mix (Fermentas UAB, Vilnius, Lithuania), 9.5 [micro]l sterile water, 1 [micro]l each of forward and reverse primers (0.2 [micro]M) and 1 [micro]l DNA template. Reaction condition was 35 cycles of denaturation for 60 sec at 94[degrees]C, annealing for 50 sec at 52[degrees]C, and extension for 50 sec at 72[degrees]C.

Sequencing of gyrA and parC: PCR products were separated by 1.5 per cent agarose gel electrophoresis, purified by PCR purification Kit (QIAGEN, Hilden, Germany) and sequenced by Bigdye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, United States). Mutations were identified by comparing translated amino acid sequences to reference gyrA sequence (Genbank accession no: U08817) or parC sequence (Genbank accession no: U08907).

Analysis of restriction fragment length polymorphism: Restriction fragment length polymorphism (RFLP) analysis was carded out as described earlier (15,16). Primers used for gyrA PCR amplification were: gyrA-F 5'-CGC GAT GCA CGA GCT GAA AAA-3' and gyrA-HinfI 5'-CCG TCT ATC AGC ACA TAA CGC ATA GCG AAA TTT TGC GCC ATA CGG ACG ATG GAG-3' Amplicon was further digested with endonuclease Hinf I (Fermentas UAB, Vilnius, Lithuania) for detection of mutations at nucleotides 272 and 284. Primers used for parC PCR amplification were: parCF 5'-AAG CCG GTG AAA TCG GCG CGC-3', paired with ParC-Sal I 5'-GAG AAT TTG GGT AAA TAC CAT CCG CAC GTC-3', ParC-Pst I 5'-GGT AAA TAC CAT CCG CAC GGC TGC-3', ParC-Hinf I 5'-AAT CCT GAG CCA TGC GCA CCA TCG AC-3' or parCR 5'-GTC GCC GTC GCG CGA ACC GAA-3'. Amplicons were each digested with Sal I, Pst I or Hinf I (Fermentas UAB, Vilnius, Lithuania) for detection of mutations at nucleotides 256, 260 and 272 of parC gene.

Statistical analysis: Association of mutation patterns with fluoroquinolone resistance was examined by Mann-Whitney test and Kruskal-Wallis test. Tests were performed using Statistic Packages for Social Science 10.0 (SPSS Inc., Chicago, IL, United States).

Results

Resistance to ciprofloxacin, ofloxacin, and lomefloxacin were observed in 95.0 (76 of 80), 95.0 (76 of 80) and 97.5 (78 of 80) isolates respectively (Table I). One isolate was susceptible to ciprofloxacin with an MIC less than 0.06 [micro]g/ml.

Together with WHO-A, 14 isolates were randomly selected for a preliminary sequencing analysis. One sensitive isolate (MIC=0.03 [micro]g/ml), two intermediated resistant isolates (MIC >0.125 [micro]g/ml and <0.5 [micro]g/ ml) and 11 resistant (MIC=1.0-16.0 [micro]g/ml) were included. All intermediate and resistant isolates had a common mutation S91F in gyrA. Twelve out of 13 intermediate and resistant isolates had a mutation at codon 95 of gyrA, among these there were mutations D95G (5 isolates), D95A (6 isolates) and D95N (one isolate). The other isolate R302 demonstrated a mutation A92P, which was seldom reported in the mainland China. Sequence analysis of parC showed a variety of mutations at codons 86, 87 and 91, while some synonymous mutations were detected in other positions (Table II). Result of 14 selected isolates, analyzed with both sequencing and RFLP method were consistent with each other (Table II). It indicated that RFLP methods could be used to detect mutations in the QRDR in the gyrA and parC, except for the A92 mutation, a seldom reported mutation site.

Since pilot sequence analysis had shown that mutations of gyrA and parC mostly took place at gyrA 91 and 95, parC 86, 87 and 91 codons, so all other isolates were re-examined by using RFLP. Theoretically, a wide type of gyrA gene amplified with the primers gyrA-F and gyrA-Hinf I could yield a 165bp product, which contains a natural Hinf I cleavage site at Scr 91 codon and an artificially created cleavage site at Asp 95 codon. Consequently, Hinf I could digest the amplified fragment to produce three products with lengths of 96 bp, 54 bp and 15 bp, respectively. When this region had mutations, Hinf I cleavage cite at Scr 91 and/or Asp 95 would be destroyed. Therefore, digestion of PCR products with Hinf I would produce restriction fragment length polymorphism to show the mutations of gyrA gene. Representative data from the experiments are shown in Fig. a. Digestion of the wild type WHO-A resulted in 96 bp and 54 bp fragements. Isolate R302 (lane 1) yielded 111bp and 45 bp fragments, indicating only a mutation at codon 91 was detected, while a mutation at Ala 92 could not be detected. All other isolates yielded a 165 bp fragement, indicated mutations at both codon 91 and 95. In other words, All isolates, including the sensitive isolate, had mutations in the gyrA gene. All isolates resistant or intermediately resistant to fluoroquinolones had a mutation at Ser 91, and a mutation at Asp 95 or Ala 92.

Three DNA fragments can be amplified from parC gene with primer pairs of parC-sal I/parCR, parC-Pst I/parCR or parCF/parC-Hinf I. Lengths of each fragment were 132 bp, 123 bp and 105 bp, respectively. When these isolates had any mutations at codons of parC 86, 87 or 91, such as D86N, S87N/D or E91A/G/R91, the cleavage sites would change and the restriction enzyme digested fragments could show some polymorphisms in length. Two isolates (lane 12 and 15) (Fig. b) could not be digested by sal I, indicating a mutation at Asp 86. Six isolates (lane 21, 24, 27, 28, 29, and 30) (Fig. c) could not be digested by Pst I, indicating a mutation at Ser 87. Three isolates (lane 32, 33, and 37) (Fig. d) could not be digested by Hinf I, indicating a mutation at Glu 91. Overall, 12 isolates had a mutation at parC86, 44 isolates had a mutation at parC87, 7 isolates had a mutation at parC91.

RFLP results were summarized in Table III. It had shown MICs and mutations of gyrA and parC for all resistant isolates in this study. A significant association (P<0.05) was observed between mutation patterns with the level of MICs. Isolates with mutations in gyrA combined with parC87 mutation showed a significantly (P<0.01) higher level of resistance to ciprofloxacin (MIC > 16.0 [micro]g/ml, 31.8 per cent (14 of 44)) than just with gyrA only mutations.

Discussion

In the last decade, the third generation cephalosporin and fluoroquinolones were recommended for the treatment of gonococeal infections worldwide. In recent years, there have been many reports on increasing number of quinolone resistant strains in Untied States, as well as in other countries (6-8,17-20), which has compromised its utility. According to the WHO Gonococcal Antimicrobial Surveillance Programme (GASP) results, the proportion of resistance was less than 16 per cent before 1995. After 1997, quinolone resistance had been increased rapidly and the resistance proportion reached to 80 per cent. It had been reported as high as 94.3 per cent in 2003 (21-22). Our results (96% resistant isolates) also showed that fluoroquinolones are no longer suitable for clinical treatment of gonorrhoea in Shanghai.

[FIGURE OMITTED]

Quinolones have a bactericidal effect when these bind with two target enzymes, DNA gyrase and topoisomerase IV, which are essential for DNA replication within the cell. The lethal effect of quinolone occurs when an intermediary complex of drug and enzymes blocks its replication, and gyrA and parC genes encode two key target enzymes. The important mechanism for the fluoroquinolone resistance in the gonococcus involves mutations in the analogous region of QRDR of gyrA and parC in Escherichia coli, which was first reported by Belland et al (9). The pattern of mutations within gyrA and parC varied in different regions. Mutations at gyrA codon 91 and 95 were more often reported than mutation at gyrA codon 92. Compared with gyrA, mutations within parC were more variable All over the world. Mutations at parC codon 86, 87, and 91 were often reported (23). An earlier study in mainland China had shown that the main mutations were S91F and D95G in gyrA, S87N and D86N in parC (24). A study conducted in Hong Kong had shown that the most prevalent mutation pattern was S91F and D95G in gyrA and S87R in parC, which accounted for about 25 per cent of total mutations; the second most frequent pattern was S91F and D95G in gyrA, which accounted for 21 per cent (25). In this study, the major mutation pattern was S91F and D95G/A in gyrA and S87R/N in parC. Mutations in gyrA that lead to substitutions of phenylalanine for serine at position 91 were consistent in All isolates in this study, while Asp95 had more mutation patterns that could also be detected in the sensitive strain. Results from this study and other studies in China had suggested that Ser91 mutation might play an important role in mediating quinolone resistance in gonococci (24,26-27). DNA gyrase had two subunits, GyrA and GyrB, which were encoded by gyrA and gyrB, while topoisomerase IV was encoded by parC and parE genes (28). It may be a primary target of fluoroquinolones. Mutations in parC could be detected simultaneously with a mutation in gyrA, suggesting that this mutation may play a compensatory role in the resistance mechanism. Most mutation patterns, which had been reported in other countries, have also been detected in Shanghai (10,23,29).

RFLP analysis had indicated that All intermediate and resistant isolates had mutations in QRDR of gyrA and/or parC. The resistance level of isolates with a mutation in gyrA combined with parC was higher than that in those isolates with only gyrA mutation. It suggests that mutations in gyrA might determine the main resistance ability to quinolone, while additional parC mutation might mediate a higher level of resistance to quinolones.

In conclusion, mutation patterns revealed in this study, showed that S91F in gyrA could serve as a quinolone resistance marker for isolates from Shanghai, while S87R/N in parC could serve as a high-level quinolone resistance marker.

Received July 20, 2007

References

(1.) Ye SZ. Antibiotics treatment of Neisseria gonorrhoeae. Chin J Dermatol 2003; 36 : 296-300.

(2.) Ye S, Su X, Wang Q, Yin Y, Dai X, Sun H. Surveillance of antibiotic resistance of Neisseria gonorrhoeae isolates in China, 1993-1998. Sex Transm Dis 2002; 29 : 242-5.

(3.) World Health Organization. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2006. Commun Dis Intel1 2008; 32 : 48-51.

(4.) Goold PC, Bignell CJ. No way back for quinolones in the treatment of gonorrhea. Sex Transm Infect 2006; 82 : 225-6.

(5.) Borgen K, van Loo I, Koedijk F, van de Laar M. Increase of gonococcal quinolone resistance in the Netherlands from 2002-2004. Euro Surveill 2005; 10 : E05 117.4.

(6.) Yang Y, Liao M, Gu WM, Bell K, Wu L, Eng NF, et al. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai. J Antimicrob Chemother 2006; 58 : 868-72.

(7.) Centers for Disease Control and Prevention (CDC). Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men--United States, 2003 and revised recommendations for gonorrhea treatment, 2004. MMWR Morb Mortal Wkly Rep 2004; 53 : 335-8.

(8.) Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Changing epidemiologic profile of quinolone-resistant Neisseria gonorrhoeae in London. J Infect Dis 2005; 192 : 1191-5.

(9.) Belland RJ, Morrison SG, Ison C, Huang WM. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol 1994; 14 : 371-80.

(10.) Unemo M, Sjostrand A, Akhras M, Gharizadeh B, Lindback E, Pourmand N, et al. Molecular characterization of Neisseria gonorrhoeae identifies transmission and resistance of one ciprofloxacin-resistant strain. APMIS Acta Pathol Microbiol Immuno1 2007; 115:231-41.

(11.) Uthman A, Heller-Vitouch C, Stary A, Bilina A, Kuchinka-Koch A, Soltz-Szots J, et al. High-frequency of quinolone-resistant Neisseria gonorrhoeae in Austria with a common pattern of triple mutations in GyrA and ParC genes. Sex Transm Dis 2004; 31 : 616-8.

(12.) Deguchi T, Yasuda M, Nakano M, Ozeki S, Ezaki T, Saito I, et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob Agents Chemother 1996; 40 : 1020-3.

(13.) World Health Organization. Sensitivity testing of Neisseria gonorrhoeae: methodologies for use by participations in the WHO Western Pacific Regional Resistance Surveillance Programme. In: WHO/WPR Regional Antimicrobial Surveillance Working Group Meeting Proceedings. 1992; 1 : 33-5.

(14.) Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI 2008; M100-S19.

(15.) Deguchi T, Yasuda M, Asano M, Tada K, Iwata H, Komeda H, et al. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1995; 39 : 561-3.

(16.) Trees DL, Sandul AL, Whittington WL, Knapp JS. Identification of novel mutation patterns in the parC gene of ciprofloxacin-resistant isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother 1998; 42: 2103-5.

(17.) Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae-Hawaii and California, 2001. MMWR Morb Mortal Wkly Rep 2002; 51 : 1041-4.

(18.) Sethi S, Sharma D, Mehta SD, Singh B, Smriti M, Kumar B, et al. Emergence of ciprofloxacin resistant Neisseria gonorrhoeae in north India. Indian J Med Res. 2006; 123 : 707-10.

(19.) Ray K, Bala M, Kumar J, Misra RS. Trend of antimicrobial resistance in Neisseria gonorrhoeae at New Delhi, India. Int J STD AIDS 2000; 11 : 115-8.

(20.) Farhi D, Gerhardt P, Falissard B, Poupet H, Poyart C, Dupin N. Increasing rates of quinolone-resistant Neisseria gonorrhoeae in Paris, France. J Eur Acad Dermatol Venereol. 2007; 21 : 818-21.

(21.) (No author Listed). The Gonococcal Antimicrobial Surveillance Programme (GASP). WHO western Pacific region, 1995. Wkly Epidemiol Rec 1997; 72:25-7.

(22.) WHO Western Pacific Gonococcal Antimicrobial Surveillance Programme. Surveillance of antibiotic resistance in Neisseria gonorrhoeae in the WHO Western Pacific Region, 2003. Commun Dis Intell 2005; 29 : 62-4.

(23.) Giles JA, Falconio J, Yuenger JD, Zenilman JM, Dan M, Bosh MC. Quinolone resistance-determining region mutations and pot type of Neisseria gonorrhoeae isolates: resistance surveillance and typing by molecular methodologies. J Infect Dis 2004; 189: 2085-93.

(24.) Wang SC, Liu YF, Su MQ, Wang Q. Correlation of in vitro susceptibilities to quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains isolated with changes in gyrA and parC in China. Di4 Jun Yi Da Xue Bao 2001; 22 : 2257-61.

(25.) Kam KM, Kam SS, Cheung DT, Tung VW, Au WF, Cheung MM. Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong. Antimicrob Agents Chemother 2003; 47 : 436-9.

(26.) Zou MX, Xia ZD, Chen SZ, Tang Y, Liu HL, Zhang GQ. Correlation between fluoroquinolone resistance and mutations of Neisseria gonorrhoeae gyrA and parC genes. Chin J Dermatol 2002; 35 : 199-202.

(27.) Wang B, Xu JS, Wang CX, Mi ZH, Pu YP, Hui M, et al. Antimicrobial susceptibility of Neisseria gonorrhoeae isolated in Jiangsu Province, China, with a focus on fluoroquinolone resistance. J Med Microbiol. 2006; 55 : 1251-5.

(28.) Lindback E, Rahman M, Jalal S, Wretlind B. Mutations in gyrA, gyrB, parC and parE in quinolone-resistant strains of Neisseria gonorrhoeae. Acta Pathol Microbiol et Immunol 2002; 110 : 651-7.

(29.) Shigemura K, Shirakawa T, Okada H, Hinata N, Acharya B, Kinoshita S, et al. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex Transm Dis 2004; 31 : 180-4.

Reprint requests: Dr Zhou Xiaoming, Department of Epidemiology, Shanghai Public Health Clinical Centre CaoLang Road 2901, Shanghai 201508, P.R. of China e-mail: xmzhou@shmau.edu.cn, ztj1127@yahoo.com.cn

Zhang Tiejun, Zhou Xiaoming [1], Zhang Jilun [2], Zhang Yinghu [3], Ren Yanhua [4], Chen Yue [5], Gu Weiming [6], Zhang Tao & Jiang Qingwu

Department of Epidemiology, School of Public Health, Fudan University, PR of China; Key Laboratory of Public Health Safety, Ministry of Education; [1] Shanghai Public Health Clinical Centre, Fudan University Affiliated, PR of China, [2] Shanghai Entry-Exit Inspection & Quarantine Bureau; [3] Shanghai Minghang Centre for Disease Control & Prevention; [4] Shanghai Pudong Centre for Disease Control & Prevention, PR of China; [5] Department of Epidemiology & Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada; [6] Shanghai Skin Disease & Sexually Transmitted Disease Hospital, PR China
Table 1. Minimum inhibitory concentration (MIC) of isolates (n=80)
for ciprofloxacin, ofloxacin and lomefloxacin

Antibiotics Distribution of MIC ([micro]g/ml)

 0.0078 0.0156 0.0312 0.0625 0.125 0.25

Ciprolloxacin 0 0 1 0 0 -1
Ofloxacin 0 0 0 0 0 1
Lomefloxacin 0 0 0 0 1 0

 Distribution of MIC ([micro]g/ml)

 0.5 1.0 2.0 4.0 8.0 16.0 32.0 64.0

Ciprolloxacin 3 5 44 8 5 14 0 0
Ofloxacin 2 1 14 43 19 0 0 0
Lomefloxacin 0 1 78 0 0 0 0 0
Antibiotics Distribution of
 MIC ([micro]g/ml) [MIC.sub.50] [MIC.sub.90]

 128.0 ([micro]g/ml) ([micro]g/ml)

Ciprolloxacin 0 2.0 16.0
Ofloxacin 0 4.0 8.0
Lomefloxacin 0 2.0 2.0

Table II. Mutations in gvrA and parC revealed by both preliminary
sequencing analysis and RFLP analysis

 Sequencing results
Isolates MIC
 ([micro] gyrA
 g/ml)
 91 92 95

WHO-A 0.016
R345 0.03 Asp to Ala
D347 0.5 Ser to Phe Asp to Gly
R307 0.5 Ser to Phe Asp to Gly
D327 1 Ser to Phe Asp to Asn
D339 1 Ser to Phe Asp to Ala
G313 1 Ser to Phe Asp to Ala
R302 2 Ser to Phe Ala to Pro
D301 2 Ser to Phe Asp to Gly
D356 2 Ser to Phe Asp to Ala
8341 4 Ser to Phe Asp to Ala
Q317 4 Ser to Phe Asp to Gly
R306 8 Ser to Phe Asp to Ala
R335 8 Ser to Phe Asp to Ala
R316 16 Ser to Phe Asp to Gly

 Sequencing results
Isolates
 parC

 86 87 91

WHO-A
R345
D347
R307 Ser to Asn
D327
D339
G313 Glu to Ala
R302
D301
D356
8341 Asp to Asn
Q317 Glu to Gly
R306 Glu to Ala
R335
R316 Ser to Arg

 RFLP results
Isolates
 gyr4 parC

 Mutation site Mutation site

WHO-A None None
R345 Asp95 None
D347 Ser-91, Asp95 None
R307 Ser91, Asp95 Ser87
D327 Ser91, Asp95 None
D339 Ser91, Asp95 None
G313 Ser91, Asp95 Glu91
R302 Ser91 * None
D301 Ser91, Asp95 None
D356 Se r91, Asp95 None
8341 Set-9 1, Asp95 Asp86
Q317 Ser91, Asp95 Glu91
R306 Ser91, Asp95 Glu91
R335 Set-9 1, Asp95 None
R316 Ser91, Asp95 Ser87

MIC: value for ciprofloxacin; MIC [less than or equal to] 0.06,
sensitive; MIC 0.125~0.5, intermediate resistant; MIC [greater than
or equal to] 1.0, resistant-. Ala92 could not be detected here,
because of no endonuclease recognized cleavage site

Table III. Minimum inhibitory concentrations (MIC) and mutation
patterns for isolates (n-80)

Mutations MIC ([micro] g/ml)

 0.5 1.0 2.0 4.0 8.0 16.0 total
gvrA 2 3 10 2 2 19
gvrA+parC86 9 1 1 1 12
gvrA-parC87 1 1 23 4 1 14 44
gvrA+parC91 1 3 1 1 1 7

MIC, value for ciprofloxacin

Some isolates had both mutations in parCS6 and parCS7, so they
had been calculated twice in this Table. The sensitive isolate
was not included
COPYRIGHT 2009 Indian Council of Medical Research
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Tiejun, Zhang; Xiaoming, Zhou; Jilun, Zhang; Yinghu, Zhang; Yanhua, Ren; Yue, Chen; Weiming, Gu; Tao
Publication:Indian Journal of Medical Research
Date:Jun 1, 2009
Words:4183
Previous Article:Extended spectrum [beta]-lactamases in Escherichia coli & Klebsiella pneumoniae & associated risk factors.
Next Article:Simple screening tests for detection of carbapenemases in clinical isolates of nonfermentative Gram-negative bacteria.
Topics:

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters